Literature DB >> 11989301

Radioiodination of monoclonal antibodies, proteins and peptides for diagnosis and therapy. A review of standardized, reliable and safe procedures for clinical grade levels kBq to GBq in the Göttingen/Marburg experience.

Th M Behr1, M Gotthardt, W Becker, M Béhé.   

Abstract

Simple and reliable methodologies for radioiodination of proteins and peptides are described. The labeling systems are easy to assemble, capable of radioiodinating any protein or, with slight modifications, also peptide (molecular mass 1000-300,000) from kBq to GBq levels of activity for use in diagnosis and/or therapy. Furthermore, the procedures are feasible in any nuclear medicine department. Gigabecquerel amounts of activity can be handled safely. The most favored iodination methodology relies on the lodogen system, a mild oxidating agent without reducing agents. Thus, protein degradation is minimized. Labeling yields are between 60 and 90%, and immunoreactivities remain > or = 85%. Other radioiodination methods (chloramine-T, Bolton-Hunter) are described and briefly discussed.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11989301

Source DB:  PubMed          Journal:  Nuklearmedizin        ISSN: 0029-5566            Impact factor:   1.379


  11 in total

1.  Gold nanorods for target selective SPECT/CT imaging and photothermal therapy in vivo.

Authors:  Boseung Jang; Seonhwa Park; Se Hun Kang; Joa Kyum Kim; Seok-Ki Kim; In-Hoo Kim; Yongdoo Choi
Journal:  Quant Imaging Med Surg       Date:  2012-03

Review 2.  Micro-imaging of amyloid in mice.

Authors:  Jonathan S Wall; Michael J Paulus; Shaun Gleason; Jens Gregor; Alan Solomon; Stephen J Kennel
Journal:  Methods Enzymol       Date:  2006       Impact factor: 1.600

3.  Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates.

Authors:  Douglas J Ballon; Jonathan B Rosenberg; Edward K Fung; Anastasia Nikolopoulou; Paresh Kothari; Bishnu P De; Bin He; Alvin Chen; Linda A Heier; Dolan Sondhi; Stephen M Kaminsky; Paul David Mozley; John W Babich; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2020-12       Impact factor: 5.695

4.  Radioimmunotherapy using 131I-rituximab in patients with advanced stage B-cell non-Hodgkin's lymphoma: initial experience.

Authors:  Maren Bienert; Ingrid Reisinger; Stefanie Srock; Beatrice I Humplik; Christel Reim; Thomas Kroessin; Norbert Avril; Antonio Pezzutto; Dieter L Munz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-04       Impact factor: 9.236

5.  Tracking Uptake and Metabolism of Xenometallomycins Using a Multi-Isotope Tagging Strategy.

Authors:  Apurva Pandey; Minhua Cao; Eszter Boros
Journal:  ACS Infect Dis       Date:  2022-03-23       Impact factor: 5.578

6.  Site-specific, thiol-mediated conjugation of fluorescent probes to cysteine-modified diabodies targeting CD20 or HER2.

Authors:  Shannon J Sirk; Tove Olafsen; Bhaswati Barat; Karl B Bauer; Anna M Wu
Journal:  Bioconjug Chem       Date:  2008-12       Impact factor: 4.774

7.  Bispecific Her2 × cotinine antibody in combination with cotinine-(histidine)2-iodine for the pre-targeting of Her2-positive breast cancer xenografts.

Authors:  Soomin Yoon; Yun-Hee Kim; Se Hun Kang; Seok-Ki Kim; Hwa Kyoung Lee; Hyori Kim; Junho Chung; In-Hoo Kim
Journal:  J Cancer Res Clin Oncol       Date:  2013-12-01       Impact factor: 4.553

8.  Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

Authors:  Eyup Akgün; Meike Körner; Fan Gao; Kaleeckal G Harikumar; Beatrice Waser; Jean Claude Reubi; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

9.  Immunolymphoscintigraphy for metastatic sentinel nodes: test of a model.

Authors:  A H Chakera; B S Nielsen; J Madsen; J Romer; P E G Kristjansen; I Buch; T Binderup; C Ingvar; A Nalla; A Kjaer; B Hesse
Journal:  Int J Mol Imaging       Date:  2011-04-28

10.  Generation and in vivo characterization of a chimeric αvβ5-targeting antibody 14C5 and its derivatives.

Authors:  Caroline Dumolyn; Steve Schoonooghe; Lieselotte Moerman; Sara Neyt; Jurgen Haustraete; Filip De Vos
Journal:  EJNMMI Res       Date:  2013-04-04       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.